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 Abstract: In this study, we investigated the inhibition of SARS-CoV-2 spike glycoprotein with HIV drugs 
and their combinations. This glycoprotein is essential for the reproduction of the SARS-COV-2 virus, so its 
inhibition opens new avenues for the treatment of patients with COVID-19 disease. In doing so, we used the 
VINI in silico model of cancer, whose high accuracy in finding effective drugs and their combinations was 
confirmed in vitro by comparison with existing results from NCI-60 bases, and in vivo by comparison with 
existing clinical trial results. In the first step, the VINI model calculated the inhibition efficiency of SARS-
CoV-2 spike glycoprotein with 44 FDA-approved antiviral drugs. Of these drugs, HIV drugs have been 
shown to be effective, while others mainly have shown weak or no efficiency. Subsequently, the VINI model 
calculated the inhibition efficiency of all possible double and triple HIV drug combinations, and among them 
identified ten with the highest inhibition efficiency. These ten combinations were analyzed by Medscape 
drug-drug interaction software and LexiComp Drug Interactions. All combinations except the combination 
of cobicistat_abacavir_rilpivirine appear to have serious interactions (risk rating category D) when dosage 
adjustments/reductions are required for possible toxicity. Finally, the VINI model compared the inhibition 
efficiency of cobicistat_abacivir_rilpivirine combination with cocktails and individual drugs already used or 
planned to be tested against SARS-CoV-2. Combination cobicistat_abacivir_rilpivirine demonstrated the 
highest inhibition of SARS-CoV-2 spike glycoprotein over others. Thus, this combination seems to be a 
promising candidate for the further in vitro testing and clinical trials. 
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1. INTRODUCTION 
 It is still unclear where the SARS-CoV-2 virus came 
from, and we have no scientific confirmation that the virus has 
passed from an animal species to a human one. However, we 
do have confirmation of the transmission of SARS-CoV-2 
virus from humans to dogs and cats. Specifically, WHO 
(World Health Organization) data describes two dogs in Hong 
Kong and one cat in Belgium, which were virus-contaminated 
from humans, but this was not COVID-19 infection in these 
animals. Shortly after the first confirmed cases of infection 
with SARS-CoV-2 coronavirus [1], COVID-19 spread rapidly 
to almost all continents of the world, with the disease 
becoming a pandemic in a very short time [2]. The number of 
patients confirmed to be infected with SARS-CoV-2 is 
increasing rapidly, and at the time of submission of this work, 
according to WHO [3], it was more than 2,500,000 cases. The 
end of this pandemic cannot yet be foreseen, and to make 
matters even worse, the estimated mortality caused by this 
virus is from about 1% to as high as 12% in the epicentre of 
the epidemic [4]. 
A host of high frequency mutations have resulted in at least 
five differentiated SARS-CoV-2 strains to date [5], therefore 
finding an effective vaccine against this virus is not to be 
expected soon. Consequently, efforts by the world scientific 
community and the pharma industry need to be focused on 
finding effective therapies as quickly as possible, in order to 
reduce the number of deaths. Finding new antiviral drugs is 
generally a costly and time-consuming process, and often 
limited with our understanding of biology [6]. Therefore, it is 
justified to consider the use of existing drugs to cure new 
diseases [7], as these drugs already have well-established 
recommended doses and regimens, known side effects, and 
ways of preventing or mitigating such effects. Equally 
important, the optimal methods of synthesizing existing drugs 
are known, so in the case of increased demand for a certain 
drug, it is easier, faster, and cheaper to expand existing 
production capacities than to design and build new ones [8]. 
Repurposing existing drugs to treat diseases can provide 
additional important benefits, and this is the possibility to 
administer multiple drugs at the same time. For example, by 
using combinations of drugs whose efficacy against the 
specific mechanism of pathogen is greater than the efficacy of 
the individual drugs, it is possible to achieve greater 
therapeutic efficacy. Another approach is to use the 
combination of several drugs with each drug acting on the 
different mechanism of pathogen [9]. In addition, the 
combined use of multiple drugs may reduce the potential for 
the pathogen to develop resistance [10]. This approach is now 
standard in the treatment of many serious diseases, including 
the treatment of cancer [11], bacterial infections [12], and 
infections with HIV [13]. 
The first attempts at treating COVID-19 disease with existing 
drugs have already been made. Thus, Kaletra 
(lopinavir/ritonavir combination) alone or in combinations 
with α-interferon, reverse transcriptase inhibitors 
(emtricitabine/tenofovir alafenamide fumarate), oseltamivir, 
and guanosine analog and reverse transcriptase inhibitor 
ribavirin, is being tested on SARS-CoV-2 patients. Trials with 
ritonavir plus ASC09, umifenovir, and remdesivir are also 
planned [14]. Antiviral drug favipiravir, chloroquine, and 
nucleotide analog remdesivir are under investigation [15]. 
Given the research to date and clinical findings, we decided to 
systematically investigate the possibility of administering pre-
existing antiviral medicines and their combinations in the 
treatment of COVID-19. As a tool for our investigation, we 
chose the VINI in silico model of cancer [16]. The VINI 
model performs virtual drug screening [17] on KEGG 
diseases metabolic pathways [18]. The high accuracy of the 
VINI model in calculating the efficacy of cancer drugs and 
their combinations has already been confirmed by comparison 
with in vitro NCI-60 data and clinical trials [16] [19]. 
Furthermore, its modular architecture enables its easy 
extensibility and virtual drug screening of nearly all diseases 
described by KEGG metabolic pathways. However, since 
there is no metabolic pathway for COVID-19 disease until 
now established, we have taken the advantage of the VINI 
model's ability to perform virtual drug screening also on only 
one specific protein.  
Like other coronaviruses, SARS-CoV-2 has four structural 
proteins, Figure 1, known as the S (spike), E (envelope), M 
(membrane), and N (nucleocapsid) proteins; the N protein 
holds the RNA genome, and the S, E, and M proteins together 
create the viral envelope [20].  
Although all four of these structural proteins are potential drug 
targets, we restricted our investigation to spike protein, which 
is essentially a glycoprotein that allows the binding of SARS-
CoV-2 to ACE2 (an angiotensin converting enzyme 2) and the 
transfer of viral RNA material to the host cell [21]. The three-
dimensional structures of spike glycoprotein were deposited 
by the same author's team at www.rcsb.org [22] on 
11/03/2013. In our study, we used one of these structures, 
designated 6VXX [23], as a target for virtual drug screening. 
  
 
Figure 1. Structural image of SARS-CoV-2. Glycoprotein 
Spike on the outer edge of virus particles give coronaviruses 
their name, crown like. 
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2. METHODS AND RESULTS 
 The task of virtual drug screening is to find drugs or 
chemical compounds (ligands) with high free energy of 
binding (in further text abbreviated ΔG) with target molecules 
(receptors), thus inhibiting them. The VINI model uses 
Autodock Vina software [24] to calculate ΔG [25] between 
receptors and ligands. By definition, ΔG has always negative 
values expressed in kcal/mol units, or zero value in case there 
is no binding between receptor and ligand. The lower these 
negative values, the greater the inhibition of the receptor by 
ligand is. For example, the binding energy of the compound 
A with ΔG = -15 kcal/mol is considered to have higher 
inhibition than the compound B with the binding energy ΔG 
= -10 kcal/mol. Although receptors can be any type of 
chemical compounds, most common receptors in biological 
processes are proteins. Unlike receptors, drug candidates are 
mostly small molecules composed of several to several dozen 
atoms. 
The quest for a vaccine against the novel SARS-CoV-2 is 
recognized as an urgent problem [26], however the 
development of an effective SARS-CoV-2 vaccine is not 
expected soon. For this, at this stage of the rapidly growing 
COVID-19 pandemic one of the most important tasks is to 
find effective drugs against SARS-CoV-2 as soon as possible. 
Various approaches were suggested, for example to use 
available angiotensin receptor 1 (AT1R) blockers, such as 
losartan, and block angiotensin-converting enzymes (ACE2) 
on human cells, thus preventing SARS-CoV-2 from attaching 
to ACE2 with its spike glycoprotein [27]. 
 Our approach is opposite: to block SARS-CoV-2 spike 
glycoprotein directly with the combination of available 
antiviral drugs expressing highest inhibition to it, thus 
preventing the virus from attaching to the human cell. 
Therefore, we decided to perform a virtual screening of the 
efficacy of the existing and approved antiviral drugs and their 
combinations on the SARS-CoV-2 spike glycoprotein. 
On KEGG portal we identified 52 FDA-approved antiviral 
drugs, 44 of them small molecules with an experimentally 
determined three-dimensional (3D) structure, 7 interferon 
drugs with FASTA sequence, and sinecatechin, a specific 
water extract of green tea leaves from Camellia sinensis. 
Furthermore, regardless of the fact that virtual drug screening 
with reduced accuracy is possible to perform on proteins 
without structure by predicting their 3D structures from 
FASTA sequences [28], we omitted interferon drugs from this 
study due to the extremely high demand of molecular dynamic 
tools [29] needed to perform in silico protein-protein docking 
and calculation of their binding free energies [30]. 
Of these small-molecule anti-viral drugs, we found 22 drugs 
indicated for human immunodeficiency virus (HIV), 6 for 
influenza and herpes simple virus (HSV), 4 drugs for hepatitis 
B virus and cytomegalovirus, and 2 for respiratory syncytial 
virus (RSV). Additionally, we excluded from the further 
analysis antiviral drugs whose binding energy to SARS-CoV-
2 is weak. The VINI model first calculated ΔG of 44 small-
molecule anti-viral drugs with SARS-CoV-2 spike 
glycoprotein. As for all other calculations of ΔG in this study, 
the VINI model used Autodock Vina software, performed 
docking and binding free energy calculation between SARS-
CoV-2 spike glycoprotein structure file with RCSB pdb id 
6VXX and each small-molecule drug 10 times, and then 
computed average of ΔG expressed in kcal/mol units. For the 
purposes of this and all subsequent simulations, the VINI 
model pulled a 6VXX structure file from the RCSB portal. For 
antiviral drugs, the VINI model used 3D structures from the 
Drugbank [31]. The results of these calculations are presented 
in Figure 2 (see the details of experimental results in Table I 
in the section Supplementary Material). 
A higher negative value indicates a higher energy of binding. 
Values below 7.0 kcal/mol represent weak binding energies. 
The highest ΔG values were shown by two HIV drugs 
atazanavir and saquinavir, and the weakest by foscarnet, a 
cytomegalovirus drug. Abbreviations used: CMV 
(cytomegalovirus), IFV (influenza virus), HSV (herpes 
simplex virus), HIV (human Immunodeficiency virus), HBV 
(hepatitis B virus), and RSV (respiratory syncytial virus). 
In the case of multi-drug cocktail therapy, the final binding 
energy depends on the order of drug binding to the protein. 
For example, the binding energy ΔG of protein P first with 
drug A and then drug B differs from the binding energy of 
protein P with drug B and then with drug A. Symbolically, 
this can be written as: 
 
𝛥𝐺(𝑃, 𝐴, 𝐵) ≠ 𝛥𝐺(𝑃, 𝐵, 𝐴)                                         (1) 
 
  
Furthermore, in the present study, and due to the possible 
adverse drug interactions, we limited our search for cocktail 
therapies with up to three individual drugs. The total number 
of single, double and triple combinations with N drugs equals 
can be expressed as: 
 
𝑀 = 𝑁 + 𝑁2 + 𝑁3                                                    (2) 
 
From (2) and because Autodock Vina simulation between 
SARS-CoV-2 spike glycoprotein and each drug was 
performed 10 times, it follows that for all single, double and 
triple combinations with N = 44 drugs the total number of 
required simulations will be 10*M, which equals 871,640. We 
estimated that such a calculation on the computing 
infrastructure available for this study may take more than two 
weeks. However, such a long calculation time is unacceptable 
given the situation caused by the SARS-CoV-2 virus, which 
requires the rapid development of new drugs. 
Because of this, the fact that HIV drugs and their 
combinations are most frequently represented in previous 
attempts to treat COVID-19 disease, and of the results given 
in Figure 2 showing that most HIV drugs have a binding 
energy to the SARS-CoV-2 glycoprotein higher than other 
antiviral drugs, we further limited the scope of virtual drug 
screenings to HIV drugs only.  
Consequently, the VINI model calculated binding free 
energies for all double and triple combinations of HIV drugs, 
and isolated ten combinations with the highest inhibition of 
SARS-CoV-2 spike glycoprotein. The results of these 
calculations are shown in Error! Reference source not 
found. (see the details of experimental results in Table II in 
the section Supplementary Material). 
All calculated values refer to -ΔG between SARS-CoV-2 
glycoprotein and drugs, and are given in kcal/mol units. Drug-
drug interactions and possible side effects of single drugs were 
examined using Medscape [32] and Lexicomp [33] drug 
interaction checkers. Combinations failing into category D (it 
Figure 2 Presented are calculated -ΔG values between the SARS-CoV-2 spike glycoprotein and 
the small-molecule antiviral drugs, expressed in kcal/mol units. 
Figure 3. 10 combinations found by the VINI model to be the most effective in inhibiting SARS-CoV-2 spike glycoprotein. 
  
is not recommended to administer these combinations without 
reducing the dosage of the individual drugs) are indicated in 
red. Combination cobicistat_abacavir_rilpivirine is 
highlighted green, as both Medscape and Lexicomp found no 
serious interaction effects. That means, no dosage reduction 
of the individual drugs is required (category C). The 
efficiency (E) of a particular combination of drugs or a single 
drug is defined as the absolute sum of the lowest (min) and 
highest (max) total binding energy: 
 𝐸 = | min(𝛥𝐺) + max (𝛥𝐺)|                                     (3) 
In the case of single drugs, the min and max binding energies 
are the same, and therefore their efficiency is absolute value 
of 2 * ΔG. 
In order to compare the relative efficacy of 
cobicistat_abacavir_rilpivirine cocktail in inhibiting SARS-
CoV-2 spike glycoprotein against cocktails and single drugs 
already used to treat COVID-19 or under the investigation, the 
VINI model calculated ΔG for the following combinations 
and compounds: Kaletra alone, Kaletra in combinations with 
oseltamivir, remdesivir and ribavirin, and 
hydroxychloroquine, remdesivir, favipiravir and umifenovir 
alone.   The results of this comparison are presented in Figure 
4 (see the details of experimental results in Table III in the 
section Supplementary Material).  
Drug-drug interactions and possible side effects of single 
drugs were examined using Medscape and Lexicomp 
software. The cocktails and single drugs that fall into category 
C are indicated in green. This category does not require a 
reduction in the doses of the individual drugs in combination. 
The combination of Kaletra with remdesivir and remdesivir 
alone are highlighted in red because remdesivir is 
investigational antiviral compound, is not yet licensed or 
approved anywhere globally, and has not been demonstrated 
to be safe or effective for any use. 
The predicted efficiency, computed as in (3), of 
cobicistat_abacavir_rilpivine combination is higher than the 
efficacy of other cocktail therapies currently used as of our 
best knowledge against SARS-CoV-2. The gain of 
cobicistat_abacavir_rilpivine cocktail in inhibiting SARS-
CoV-2 spike glycoprotein over Kaletra is 13,62%, over 
Kaletra with oseltamivir cocktail 7,25%, and over Kaletra 
with ribavirin cocktail 6,98%. The gain over single drugs used 
or planned to be used is much higher, and is 69,27% over 
favipiravir, and 61,67% over umifenovir. The gain over 
hydroxychloroquine is not relevant because this drug works 
on a completely different basis, by suppressing the immune 
system overreaction. Only the predicted efficacy of Kaletra 
with remdesivir cocktail is higher than of 
cobicistat_abacavir_rilpivirine combination, and equals 
4,83%. However, remdesivir is not an approved drug, but a 
compound still under investigation in recently approved 
clinical trials. 
From the results, one can also discern a slight fluctuation of 
ΔG results for the same receptor-ligand pair in different 
experiments. Thus, regardless of the fact that ΔG was 
calculated ten times for each receptor-ligand pair, in the first 
experiment ΔG for indinavir was -9.63 kcal / mol (Table 1), 
and in the second experiment ΔG was -9.50 kcal / mol (Table 
2). Such fluctuations are expected and are related to the 
stochastic nature of Autodock Vina, which each time initiates 
simulation of the same receptor-ligand pair from different, 
randomly selected initial coordinates. 
3. DISCUSSION AND CONCLUSION 
      The SARS-CoV-2 spike glycoprotein is a key factor in the 
binding of the virus to angiotensin-converting enzyme 
(ACE2), allowing the virus to transmit its RNA material to the 
host cell, and hence its further reproduction. Effective 
inhibition of the SARS-CoV-2 spike glycoprotein can slow or 
even completely inhibit the reproduction of the SARS-CoV-2 
virus, thus increasing the chances of the host immune system 
Figure 4. An overview of the efficacy of cobicistat_abacavir_rilpivine combination of HIV drugs with respect 
to the already used or planned combinations of drugs or individual drugs. 
  
to fight against the virus. The results of our study provide 
scientific confirmation of the high efficacy of some 
combinations of approved HIV drugs, and compounds still 
under investigation, in the inhibition of SARS-CoV-2 spike 
glycoprotein. Further application of these results may pave the 
way for new, even more effective therapies than those 
currently used in the treatment of COVID-19. 
Among the ten most effective HIV drug combinations 
predicted by the VINI model to be the most effective in 
inhibiting SARS-CoV-2 spike glycoprotein, the 
cobicistat_abacavir_rilpivirine combination stands out. 
Although ranked 8th regarding its efficiency, it is, due to its 
relatively low toxicity and acceptable drug-drug interactions, 
suitable for use at standard doses of individual drugs without 
the need for their adjustment. 
The predicted efficacy of this combination in the inhibition of 
SARS-CoV-2 spike glycoprotein is greater than the efficacy 
of the drug combinations and the individual drugs, which, to 
the best of our knowledge, have been tried, or are planned to 
be tried in the treatment of COVID-19. These are Kaletra 
(lopinavir_ritonavir combination), Kaletra in combination 
with oseltamivir, Kaletra in combination with ribavirin, and 
hydroxychloroquine, favipiravir and umifenovir as single 
drugs. 
The efficiency of the cobicistat_abakavir_rilpivirin 
combination predicted by the VINI model is slightly lower 
than the efficacy of the Kaletra_remdesivir combination. 
However, remdesivir is a compound under investigation, and 
its possible side effects and interactions with lopinavir and 
ritonavir are still unknown. 
From the results obtained, it can also be concluded that the 
order of action of individual drugs in some combination on 
the SARS-CoV-2 spike glycoprotein does matter. Thus, the 
highest ΔG of cobicistat_abacavir_rilpivirin combination on 
this glycoprotein is achieved when it first binds cobicistat, 
then abacavir, and at the end rilpivirine. This indicates that a 
3 times daily regimen in which cobicistat is given first, then 
abacavir, and at the end rilpivirine, could further increase the 
effectiveness of this combination therapy. A detailed 
pharmacokinetic analysis of the effects of individual drugs 
will be required to evaluate the benefits such a regimen may 
possibly bring, and this goes beyond the scope of this study. 
Therefore, a clinical trial of the combination of 
cobicistat_abacavir_rilpivirin with a limited number of 
COVID-19 patients who are in moderate severe and severe 
condition is warranted. 
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